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Abstract
Establishing how to effectively manufacture cell therapies is an industry-level problem. Decentralised manufacturing is
of increasing importance, and its challenges are recognised by healthcare regulators with deviations and comparability
issues receiving specific attention from them. This paper is the first to report the deviations and other risks encoun-
tered when implementing the expansion of human pluripotent stem cells (hPSCs) in an automated three international
site–decentralised manufacturing setting. An experimental demonstrator project expanded a human embryonal carci-
noma cell line (2102Ep) at three development sites in France, Germany and the UK using the CompacT SelecT
(Sartorius Stedim, Royston, UK) automated cell culture platform. Anticipated variations between sites spanned mate-
rial input, features of the process itself and production system details including different quality management systems
and personnel. Where possible, these were pre-addressed by implementing strategies including standardisation, cell
bank mycoplasma testing and specific engineering and process improvements. However, despite such measures, un-
expected deviations occurred between sites including software incompatibility and machine/process errors together
with uncharacteristic contaminations. Many only became apparent during process proving or during the process run.
Further, parameters including growth rate and viability discrepancies could only be determined post-run, preventing
‘live’ corrective measures. The work confirms the critical nature of approaches usually taken in Good Manufacturing
Practice (GMP) manufacturing settings and especially emphasises the requirement for monitoring steps to be included
within the production system. Real-time process monitoring coupled with carefully structured quality systems is
essential for multiple site working including clarity of decision-making roles. Additionally, an over-reliance upon
post-process visual microscopic comparisons has major limitations; it is difficult for non-experts to detect deleterious
culture changes and such detection is slow.
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1 Introduction
The purpose of the work reported in this paper was to establish
and address the issues associated with automated expansion of
human pluripotent stem cell (hPSC), a living material, by
partners at three developmental international sites in
Germany, France and the UK using a common automation
platform. This is an instance of distributed automated aseptic
manufacturing of a complex cell therapy. The aim was to run
batches for multiple automated passages at each site from a
standardised starting material that had been banked at one of
the sites. This is significant for a number of reasons: (i)
manufacturing of cell therapies for global markets will require
aseptic manufacturing in multiple locations in different coun-
tries (sometimes within different regulatory regimes); (ii)
manufacturing may be close to the point-of-care or use rare
(autologous) starting materials [1, 2]; and (iii) the emerging
model for international human-induced pluripotent stem cell
(hiPSC) haplobanking requires the sharing of starting mate-
rials and their subsequent expansion in different countries and
within different regulatory regimes [3–5]. The requirement to
manufacture products at multiple sites is recognised by both
EU and US regulators as challenging for biological products
of this complexity [6, 7]. In particular, this requires the dem-
onstration of comparability to ensure that the products are the
same after any change. Essentially, in this case, this means that
the products at each site and the processes to create them are
the same. The practical experimental demonstrator project
presented here succeeds a workshop at Trinity Hall,
Cambridge, UK [8] held in 2015; the workshop confirmed
the context for the present work. It also follows comparability
experiments on process changes [9, 10] using the same auto-
mated process platform.
Table 1 shows how the current work fits with past work
emphasising how achieving comparability within distributed
manufacturing has been recognised as a key research gap by
the cell therapy community and a challenge by the regulator.
The contribution of the work presented here is that it is the first
published account of the issues and deviations encountered in
attempting to achieve comparability, essentially the produc-
tion of the same product, at three sites for a biological product
representative of a pluripotent stem cell therapy.
Resolving the differences due to manufacturing at different
sites requires that a robust cell culture process protocol and
that a common automated processing platform are used at
each site. It also assumes the availability and use of a
standardised cell line that can be used as a comparator.
These are described fully below. With these in place, differ-
ences in output are assumed to be a consequence of physical
and organisational differences between the sites. Differences
in output were anticipated to be an increased statistical varia-
tion in process output. However, it was also apparent that
other issues would arise during the execution of the
demonstrator, but it was not apparent what these issues would
be; all project partners understood that a truly informed and
practical perspective on the issues encountered would only
become apparent after the experiment.
It was anticipated that the work would have three
phases: (i) a preparatory phase to identify overall process
transfer issues as a consequence of working across inter-
national borders within the EU, whereby the transfer takes
place from and to regulated development and manufactur-
ing facilities; (ii) a second phase of identifying machine-
and protocol-specific issues associated with the expansion
and differentiation of cells equivalent to those of thera-
peutic quality at multiple sites; and (iii) a third phase of
routine culture followed by characterisation of the cells to
measure the variations from different automated platforms
and laboratory locations.
The intent of this experiment was to be a demonstrator
emulating the aseptic automated manufacturing of thera-
pies at multiple production sites in order to expose the
practical issues encountered in this activity. A key aspira-
tion was the measurement of the additional variation in
the product as a consequence of manufacturing at more
than one site given that the main automated processing
machine to be used was already installed and operating
at each site. An ideal experiment would include three
production facilities following the same quality manage-
ment system (QMS) across the three sites. However, it is
important to recognise that several pragmatic decisions
were made to facilitate the experiment as shown in
Table 2. The largest of these is that the three facilities
did not operate to GMP conditions but were considered
to be close to it because of their translational development
orientation. The risks arising from these decisions are
shown in Table 3.
Overall, analysis of the results obtained highlighted the
significance of unexpected differences and deviations dur-
ing the second phase of the project. This included the
challenges in handling low-grade contamination, whilst
highlighting the crucial importance of managing this. As
the risks identified in Table 3 show, this is most likely a
reflection of the settings and gaps in the preparation and
execution of the experiment. This is a consequence of the
availability of resources including people and time, and of
the difficulty of imposing a consistent quality system and
close to GMP-like approach on three different develop-
ment organisations in the absence of commercial drivers.
This publication consequently reports on the results of an
experiment to measure and record deviations (both anticipated
and unanticipated) when the mature manufacturing protocol
of a pluripotent stem cell–derived therapeutic is transferred
across multiple development sites. The paper begins with a
presentation of the materials and methods used, the key results
of the culture process followed by a description of the
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Table 1 A comparison of the present work with past and other key enabling work to identify the research gap in understanding comparability in the distributed manufacturing of pluripotent stem cell
therapies
Therapeutic approach Cell types Manufacturing strategy Regulatory context Approach Number of
locations
Contribution, significance and
research gap
Reference
Clinically led autologous
cell therapy
All Multiple hospital based.
See also [11, 12]. For
alternatives see [2].
US [6] and EU [7] regulatory
environment.
Industry consultation Many Identifies the importance of
comparability to the roll out of
clinically pulled therapies in
multiple sites and consequently to
the growth of the regenerative
medicine industry.
[1]
Generic cell therapies All Process scaling and
decentralised supply
from sites.
US [6] and EU [7] regulatory
environment.
Stakeholder workshop Many Identification of key research gaps
within comparability to be
addressed by community.
[8]
Mesenchymal cell
therapy
hMSC Automated process US [6] and EU [7] regulatory
environment.
Experimental
demonstrator
One Measuring comparability of
automated and manual process
steps
[10, 13–15]
Embryonic stem cell
therapy
hESC Automated process. US [6] and EU [7] regulatory
environment.
Experimental
Demonstrator
One Demonstration of automated hESC
culture. Core enabler for work in
[16] and current work.
[17]
Haplobanked cell therapy,
see [3–5, 18]
IPSC Automated process
(based on [16]; and
also see [19]
addressing cost).
US [6] and EU [7] regulatory
environment.
Experimental
demonstrator
One Measuring comparability of
automated and manual process
steps.
[9]
Embryonic/Pluripotent
cell therapy standard
hPSC Reference cell lines.
See also [20].
US [6] and EU [7] regulatory
environment.
Experimental
demonstrator
- Establishment of hPSC reference
cell lines. Core enabler for current
work.
[21]
Biologics - All US [6] and EU [7] regulatory
environment.
Guidelines and
overview
- Approaches to safety [22] and
control of contamination [23]. See
also [24].
[23]
Pluripotent cell therapy hPSC Decentralised
automated process
emulating multiple
hospital or industrial
sites.
EU [7] regulatory environment. Experimental
demonstrator
Three
international
Practical identification of the
comparability issues encountered
in manufacturing in multiple sites.
Identification of the criticality of
agreed approaches to process
monitoring and the handling of
deviations and the monitoring of
low-grade infection.
Reported here
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deviations encountered. It then continues with a discussion of
the results obtained, including the deviations encountered and
their consequences. It concludes with a summary of the learn-
ing from the experiment.
2 Materials and methods
The production protocol was performed at three international
developmental sites. These were the Centre for Biological
Engineering, Loughborough University (UK); the Fraunhofer
Institute for Biological Engineering (Germany) and Institute for
Stem cell Therapy and Exploration of Monogenic diseases (I-
Stem, France). The developmental sites are here referred to as
sites, 1, 2 and 3; these numbers have been randomly assigned.
The quality assessment was performed at NIBSC (UK).
2.1 Cell lines
This work has been executed using the embryonal carci-
noma (EC) 2102Ep cell line (2102Ep, GlobalStem,
USA) derived from primary human testicular teratocar-
cinoma [21]. The cells were expanded in-house to make
a master cell bank, followed by corresponding working
Table 2 Pragmatic decisions made during the design of a three-site experiment
No Ideal scenario Replacement Justification
1 Use the production process for a pluripotent
stem cell derived therapy to transfer across
to three production facilities.
Banking of pluripotent stem cell-like-cells (the
surrogate product) used as the production
process in this experiment. The cell line
chosen is the embryonal carcinoma cell line
EC 2102Ep [21].
Both cells and production protocols need to be
publicly or commercially available with
permissions to transfer across multiple sites. In
this experiment, the chosen cell line is
commercially available, and the protocols
derived are not commercially sensitive, hence
they can be transferred across the three sites.
Embryonal carcinoma cell lines test positive for a
panel of gene expression markers common
with pluripotent stem cell lines.
The 2102Ep cell line is permitted for use in all
the countries where this experiment is being
carried out, in contrast to human embryonic
stem cells (hESCs) which are restricted for use
in many countries [25]
2 Use three production facilities with a GMP
certificate for production of hPSC-derived
cell therapies
Three development facilities, which are currently
working towards industrialisation of cell
therapy products. The deviations in the
non-GMP setting highlight and confirm areas
of risk.
GMP-qualified labs are not practically available
for such an experiment, as there is currently
insufficient GMP capacity [26], and they have
very high-associated costs [11].
The use of a non-GMP setting in development
facilities should provide sufficient sensitivity
to detect failure.
A gap analysis based on EU Regulations [7] and
WHO Biology Laboratory Guidelines [22]
was performed (Table 3) to demonstrate the
differences anticipated and observed by the
site teams.
3 Use of a production process for a mature
therapy where the production process has
been developed sufficiently to reflect its
mature status.
The experiment uses an embryonal carcinoma
cell line as a surrogate product and a
production protocol automated on the
Compact SelecT (Sartorius Stedim, Royston,
UK) which is a development tool for
expansion of adherent cell cultures.
Mature production processes are product
specific. For pluripotent stem cell-derived
products production processes are currently
limited or non-existent.
Use of product surrogates allows for
identification of critical process parameters.
Automation is essential in anymature production
pipeline.
4 In-process quality control is automated, and
the batch records are maintained by the
automated platform.
Not all the Compact SelecT platforms utilised at
the three sites had integrated microscopes for
the in-process visual verification of the culture
progress. In this case, the operators at the sites
are to manually view the flasks.
A verification of the progress of the production
process at each step is not a regulatory
requirement for a qualified process.
During this experimental process, operators will
manually view the flasks and take images.
These images are to be shared with the
experimental teams at the three sites. Well
maintained laboratory notes are to act as the
batch record.
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cell banks. All procedures performed were in accordance
with the ethical standards of the institutional and/or na-
tional research committee and with the 1964 Helsinki
declaration and its later amendments or comparable eth-
ical standards. EC lines are robust cell lines that allow
for comparison studies between laboratories since they
grow without the need for feeder cells, are relatively
simple to passage and resist spontaneous differentiation
and are a rich source of the proteins and mRNAs used to
characterise hPSCs [21]. A National Institute for
Biological Standards and Control (NIBSC) hiPSC line,
NISBC8, a quality-controlled bank of 2102Ep embryo-
nal carcinoma cells, the F9 embryo teratocarcinoma cell
line and a UK Stem Cell Bank (UKSCB) NIBSC internal
Table 3 Risks identified during the experimental design
Ideal scenario (GMP production) Pragmatic scenario (development laboratory) Risk
Facility
The design and construction of the facility is
based on its suitability to the production
environment where the needs of the product
are paramount. There is usually separation of
areas to minimise mix-ups/contamination and
careful attention to process flows. There are
prescriptive regulations regarding lighting,
plumbing, sewage and washing facilities
under GMP, as well as specific product
quality assessment tests and acceptance
criteria at different production stages.
Design and construction of the research and
development facilities are normally prescribed
by health and safety concerns for the users.
Segregation might be required for preventing
mix-ups or contamination, but it is not
obligatory. Other features of the facility
including construction etc. are not universally
defined. These decisions are set locally so are
often not comparable across sites.
Potential increased risk of process deviation (for
example due to facility temperature variances)
and increased risk of product contamination
and failure to pass acceptance criteria.
Production team
Responsibilities of all the operators and
supervisors should be in written procedures.
The production team and supervisors will be
fully trained in their respective roles.
The training in the tasks will be based on the
experiments to be performed.
Increased risk of deviations to the protocols.
Training assessed and recorded formally and
regularly
Critical assessment made of the protocols of each
laboratory.
Release of product performed by a Qualified
Person (QP) leading a team of quality
assurance and quality control professionals.
There is often no product other than the results
from testing and they are released by the
supervisor of the team.
Equipment and consumables
Equipment for use in production and testing
must be qualified for the use. Data generating
equipment for product testing must be
calibrated regularly. The accuracy, sensitivity,
specificity and reproducibility of test methods
should be established and documented.
Equipment must be appropriately, maintained
and calibrated. Equipment qualification with
formal record keeping is not obligatory.
Increased risk of incorrect read-outs.
Automation platform
Automation platform qualified for the unit
operation in the site. The site provides the
required environment for the automation
platform.
Automation platform for the unit operation
installed correctly.
Increased risk of protocols varying across sites
Procedures
All SOPs are drafted based on guidelines by
qualified personnel and approved by the
quality control (QC) unit of the production
facility.
SOPs are based on the local requirements and the
equipment manuals. They are written and
approved by research and development staff
rather than quality or regulatory professionals.
Increased risk of protocols varying across sites.
Increased risk of product variability.
SOPs are standard for the activities in the
production facility. Each production task will
be recorded in batch records following the
SOPs for the production facility.
It is possible that different experiments have
‘experimental operating procedures’which are
specific to the experiment and may override
SOPs for the facility.
All batch records are signed off by the operating
personnel along with the personnel verifying
the steps (dual control of procedures/records).
These are maintained long term.
Sign-off for experimental records is not a formal
process. Often operator sign-off is sufficient.
Testing is prescriptive and will be performed in
the same manner for all batches.
Testing is based on the requirements of the
experiment.
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standard n210EP-UKSCB were used as flow cytometry
control lines.
2.2 Manual cell culture protocol
Unless otherwise stated, all reagents and consumables used
were purchased from Fisher Scientific, Leicestershire, UK.
EC 2102Ep were expanded at high density on T175-cm2 tis-
sue culture plastic flasks (Corning Lifesciences, NY, USA) at
37 °C in a humidified chamber containing 5% CO2 in air. The
growth medium used was Gibco DMEM high glucose with
glutamax supplemented with 10% (v/v) foetal bovine serum,
qualified and heat-inactivated (FBS). The growth medium
was changed every 48 h.
Cells were passaged every 3 days; the spent medium was
aspirated, and the cells were washed with PBS (−Ca2+/
−Mg2+), 250 μl/cm2. The cells were detached using 7 ml
1xTrypsin-EDTA (0.25%, v/v) phenol red solution for 5 min
at 37 °C. Cells were passaged every 3 days when flasks were
heavily confluent and split according to cell count and the
appropriate required cell density. Wash medium was added
at twice the volume of Trypsin-EDTA used and the cell sus-
pension was centrifuged for 5 min at 300×g.
2.3 Cell counting
The NC-3000™–automated image cytometer (ChemoMetec,
Denmark) was used to perform cell counts. Cell counts and
viability were measured using the cell viability and cell count
assay following the manufacturer’s instructions. The assay uti-
lises a commercially available pre-mix of acridine orange base
N, N, N′, N′-tetramethylacridine-3,6-diamine monohydrochloride
(AO) uptake and 4′,6-diamidino-2-phenylindole, dilactate (DAPI)
exclusion (Solution 13, eChmoMetec, Denmark). Solution 13was
mixed into the cell suspension at a ratio of 1:19; prior to loading
into a NC-Slide-A8 (eChmoMetec, Denmark).
2.4 Cell banking and cryopreservation
AnEC 2102Epmaster cell bankwas created in-house; all cells
were banked at Passage 46 (P46) and a total of 353 ml
cryovials each containing 1.5 × 107 cells were suspended in
CryoStor solution according to the manufacturers protocol
(Sigma-Aldrich, UK). The vials were stored in a Mr Frosty
CoolCell® passive cooling device for 24 h at − 80 °C, before
being transferred to the vapour phase of liquid nitrogen where
they were stored prior to experimentation.
2.5 Setup of comparability experiment
The team from site 1 coordinated the experiment as well as
being the first site for the experiment. The experiment coordi-
nation package included producing the 35-vial-sized working
bank for the experiment which was distributed under con-
trolled shipping conditions to the other two sites along with
essential consumables including media, pipettes and tubing;
sharing a common operating procedure for the CompacT
SelecT; and training on the CompacT SelecT.
2.6 Automated cell culture
2.6.1 Machine
The TAP Biosystems’ CompacT SelecT–automated cell cul-
ture platform (Sartorius Stedim, Royston, UK), which utilises
an incubator carousel to store cell culture flasks, multiple peri-
staltic pumps to dispense cell culture reagents and a robotic
arm to replicate many of the process steps involved in manual
cell culture, was utilised in this study. This platform also in-
corporated a Cedex analyser–automated cell counter (Roche,
Switzerland); the system utilises Trypan blue exclusion and
automated imaging software to determine viable cell density,
viability and aggregate rate. The CompacT SelecT has previ-
ously been demonstrated for the culture of hMSCs [13, 14,
27], hESCs [17] and hiPSCs [10, 16] as aggregates.
2.6.2 Machine preparation and calibration
Prior to the performance of any automated protocol on the TAP
Biosystems’ CompacT SelecT platform, the machine was pre-
pared for use by ensuring a sufficient number of pipette tips were
loaded, sufficient new T175-cm2 flasks were available, that ade-
quate volume of reagents were loaded aseptically and that the
required sterile plastic tubing (Watson-Marlow Pumps,
Falmouth,UK)was connected to allow for reagents to be pumped
using the peristaltic pump system. To ensure that the required
volumes of reagent are dispensed throughout each protocol, a
calibration step is performed prior to each CompacT SelecT pro-
tocol. Briefly, the plastic tubing was primed, and a small volume
of reagent was dispensed into a BD Falcon TMT175-cm2 tissue
culture flask (BD Bio-sciences, San Jose, USA). The flask was
then ‘borrowed’, and the contents were weighed on digital scales.
‘Borrowed’ refers to the programming terminology whereby the
machine is instructed by the operator to eject the flask from the
machine. This step allows the operator to determine the volume of
reagent dispensed, assuming that 1 mL of reagent weighs 1 g.
This value can then be entered into the CompacT SelecTsoftware
in order to calibrate the peristaltic pump system, which adjusts the
subsequent dispensing steps accordingly.
2.6.3 Dry run and automated culture emulation
The CompacT SelecT–automated protocol consisted of the
following: (i) dry run—a software compatibility run with each
of 4 sub-protocols includingmedia change, passaging the cells
split 1:3 and 1:1 and sampling (but without cell culture
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media). (ii) Wet run—using PBS/ddH2O to emulate culture
media, with each of four sub-protocols after repair service
and preventative maintenance (PM).
2.6.4 Automated cell culture protocol
Three cryovials of 2102Ep cells were thawed and cells from
each vial were transferred directly into a T175-cm2 flask.
T175-cm2 flasks were loaded into the CompacTand incubated
in the CompacT incubator at 37 °C with 5% CO2. Media
exchange was performed 48 h post-seeding and cells were
sub-cultured the following day (day 3) into 3 daughter T175
cm2 flasks according to cell count, so that each daughter flask
contained 1.5 × 107 cells, equivalent to 85,000 cells per cm2
(Fig. 1). Cells were sub-cultured for six passages (Fig. 2). Cell
samples were collected for flow cytometry analysis after each
passage and stored at – 80 °C.
2.6.5 Culture protocol optimisation/repeatability
improvement
An automated protocol was first derived for pluripotent stem
cells expansion by observation of manual culture by
Loughborough University engineers of expert Cambridge
University biologists [16] working with a well-defined
hiPSC line. Parameters for this protocol were then adapted
to the expansion of the 2102Ep cells [19]. The initial protocol
was based on 1:3 or 1:4 split ratios for cell passage. The
protocol was revised and improved, and a cell count step
was added whilst performing the splits to both manual and
CompacT automated protocols. The CompacT improved pro-
tocol included increased shaking time and pipette mixing with
elimination of sample pooling steps since the machine does
not use centrifugation and permit flask-by-flask sampling.
2.7 Immunophenotyping using flow cytometry
Immunophenotyping using flow cytometry (BD FACSCanto
II, San Jose, CA) was performed on samples from site 1. The
complete analysis was performed by NIBSC to remove any
potential bias in the interpretation of results. Excess cell sus-
pension was removed from cells at passage 1-5. The cells were
centrifuged at 300×g for 5 min prior to suspension in CryoStor
freezing solution and storage at – 80 °C. Since the detached
cells from passage 6 were at the end of the experimental pro-
cedure, all cells were frozen down and stored, as opposed to
just the excess cells. Prior to staining the cells were thawed
and pelleted via centrifugation for 5 min at 300×g, room tem-
perature, washed in 1xPBS, and then fixed in Cytofix/
Cytoperm solution (BD Biosciences, UK) at 4 °C for 20 min.
Fixed cells were washed with 1xPBS and assessed for the
stem cell markers, Oct-4, Nanog, SSEA4, SSEA1 and TRA-1-
60, using specific antibodies (R&D Systems Cat: 560477,
506122 and 561300). Briefly, cells were permeabilised with
BD perm/wash buffer for 10 min at 4 °C. The antibodies
(concentrations according to manufacturer’s instructions)
were incubated for 20 min at 4 °C and were protected from
light. The cells were then washed in A perm/wash buffer (×3)
and run on the BD Canto II flow cytometer according to man-
ufacturer’s instructions.
2.8 Robust sample handling and logistics
Frozen 2102Ep cryovials were transferred between sites via
courier and on dry ice in a polystyrene container. Sampling
was performed after each passage step manually and the re-
maining cell suspension of each flask were added to CryoStor
solution and were frozen at – 80 °C.
3 Results
As has been described in “Section 1”, this experiment is a
demonstrator where it was anticipated that practical issues
would be encountered. It is therefore challenging to present
the results in a conventional serial manner. Consequently, we
present them structured as those arising in the preparatory
Fig. 1 Schematic summary of the automated cell culture protocol on the
CompacT SelecT. The robotic arm pours off the media prior to a washing
step in PBS to remove any residual media. The trypsin pour-off step is
performed so that only a minimal coating of the chelating agent is in
contact with the cells since the automated system is incapable of
centrifugation. This is followed by quenching with FBS enriched media
whereby the proteins in the FBS neutralise the trypsin. The cells are
mixed, and a cell count is performed using the Cedex automated
system. An appropriate volume of media is then added to the new
flasks to obtain the desired seeding density
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phase, biological variations and other key subsequent themes
that arose during culture, as below.
3.1 Preparatory phase
The organising site team visited the three sites prior to
starting the experiment. Several differences and deviations
were identified between the three manufacturing sites pri-
or to, and during the execution of the automated expan-
sion of the 2102Ep cell line. These variations were mainly
linked to the processing machine; these included differ-
ences in air flow, incubator temperature and software
compatibility. Furthermore, organisational issues were al-
so apparent (Table 4). To elaborate, (i) laminar and nega-
tive air flow deviations occurred, although these were
minimal and remained within specification, thus the con-
sequences were negligible. (ii) The incubator CO2 % at
site 2 was reading unusually high (26%) despite servicing
being carried out; hence, an alternative (iii) incubator was
used to minimise any detrimental consequences on the
culture. Incubator temperature was 0.6 °C higher at site
3, although the effect to the 2102Ep line would be mini-
mal due to the robust nature of the cells. (iv) The
integrated microscopy system was absent in the automat-
ed system used at site 1 due to it being a first-generation
machine, as a result, visual monitoring of cell phenotype
was therefore omitted from the protocol. It is possible that
if the addition of a visual monitoring step had been in-
cluded in the SOP, this step would have detected the con-
tamination that was observed at site 3. (v) Software in-
compatibility issues manifested themselves as the inability
of the three machines to use the same software protocol
across the three sites. Consequently, at site 3, the protocol
required some adaptation.
Other differences included those in the quality systems of
the sites. The three sites had been chosen because they all
work on pre-production development activities and have a
laboratory-based quality system that has been developed to
include a demonstration of the reliability of results generated,
and importantly that reflected the quality systems of associat-
ed production facilities. However, several differences were
identified during the preparatory phase. A significant example
of the differences between sites were the standard operating
procedures (SOPs) for regular cleaning. For instance, at site 1,
the SOPs were developed based on the understanding that a
two-stage cleaning with manual wiping (first with the
Fig. 2 Schematic representation of the EC 2102Ep expansion protocol, demonstrating the three cryovials that were thawed and initially seeded into three
corresponding T 175 cm2 prior to expansion in triplicate over six passages
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disinfectant followed by a rinse) of every surface was the best
method for regular cleaning. In contrast, at site 3, the SOPs
reflected the procedures in the production facility where fre-
quent vapour hydrogen peroxide decontamination was suffi-
cient. In both cases, the effectiveness of the respective regular
cleaning was validated for the associated production facility.
However, this validation was not conducted in the develop-
ment laboratories; hence, the two quality systems could not be
directly compared. This difference in the cleaning procedures
particularly affects the regular cleaning of equipment such as
biological safety cabinets, incubators and the automated pro-
cessing machine. Consequently, it was difficult to pinpoint the
exact causes of contamination.
Other instances of differences in the quality systems en-
countered included the following: different maintenance re-
gimes for essential equipment including biological safety cab-
inets, incubators, autoclaves; sharing or otherwise of pipettes;
standards for training of new staff; and routine testing for
contamination such as mycoplasma.
3.2 Biological variations across sites
3.2.1 Cell culture
The cells grew as a uniformmonolayer with a high nucleus-to-
cytoplasm ratio and prominent nucleoli [21]. 2102Ep cells
were attached to untreated tissue culture plastic flasks and
were maintained at high density. Cells were passaged every
3–4 days according to cell count and confluency. Cells main-
tained this morphology following several manual passages;
cell clusters were also observed from the onset of the manual
expansion, as the cells became increasingly confluent, al-
though these observations were not recorded.
3.2.2 Cell numbers and viability
The result of the Cedex–automated cell count demonstrated a
flask-to-flask variation in the total cell number following the
first passage at all sites; this was despite the identical initial
cell seeding density (Fig. 3). The total number of cells at site 1
initially decreased to a combined average of 1.92 × 106 cell/ml
at passage 3 (n = 9, SD = ± 0.25 × 106 cell/ml), prior to
increasing to 2.92 × 106 cell/ml at passage 4 (n = 6, SD = ±
0.64 × 106 cell/ml). Despite this spike in cell number, from
passage 5 onwards, there was a significant decrease in the total
cell number recorded, with less than 0.5 × 106 cell/ml at pas-
sage 6. It is postulated that the drop in cell number at passage 3
was due to the initial change to an automated culture; the
subsequent increase in cell number at passage 4 is potentially
due to the cells acclimatising to the change in culture process-
ing, in particular the requirement for additional pipetting in the
automated protocols to reduce cell clumping.
At site 2, the initial increase in cell number to 3.45 × 106
cell/ml at passage 2 (n = 9, SD = ± 0.38 × 106 cell/ml) was
followed by a significant decrease in total cell number at pas-
sage 4; this continued at both passages 5 and 6, whereby less
than 0.5 × 106 cells were counted respectively. As speculated
above, this may be an inherent artefact of the cells adapting
from manual to automated cultures.
Cell viability reduced substantially following passage 4
to approximately 80% at both sites 1 and 2 (Fig. 3B).
Flask-to-flask variability was low at both passages 3 and
4 for both sites 1 and 2; deviations between flasks only
began to present following passage 5. The trend in reduc-
ing cell viability with increasing passages continued for
the majority of the flasks following passages 5 and 6 at
both sites 1 and 2. In addition, flask-to-flask variation
increased at both sites; in particular at site 2, whereby
viability ranged from 66.4 to 81.9% at passage 5 and
48.3 to 88.9% at passage 6. An increase in cell viability
at passage 6 was observed in 3 of the flasks expanded at
site 2 only.
At site 3, the experiment was terminated at passage 3 due to
higher observed deviations in cell viability data and lower cell
growth, most likely as a result of cell culture contamination.
Specifically, cell viability at site 3 were visibly lower
Table 4 Summary of major differences and deviations identified between sites prior to and during expansion of EC 2102 Ep cells
Specification Site 1 Site 2 Site 3
Air flow
Laminar flow: 0.35–0.55 (m/s)
Negative flow: 0.4–0.7(m/s)
Laminar flow: 0.435
Negative flow: 0.647
Laminar flow: 0.454
Negative flow: 0.504
Laminar flow: 0.481
Negative flow: 0.576
Incubator CO2 % 5% 26%* 5.5%
Incubator temperature 37 °C 37 °C 37.6 °C
Lab based SOPs for machine
decontamination/cleaning
Two-stage cleaning, disinfectant followed
by rinsing and manual wiping
Vapour hydrogen peroxide
decontamination
In-house vapour hydrogen
peroxide decontamination
Organisational issues First machine Required machine move and
use of alternative incubator
Prohibition of weekend
working
*The sensors were faulty/not calibrated at site 2, resulting in such a high CO2 read-out
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following passage 3 with greater flask-to-flask variation, be-
tween 77.7 and 93.2% recorded.
In addition, the flask-to-flask variation in cell count in-
creased at all three manufacturing sites from passage 2 on-
ward. The variations were more apparent in the earlier
passages. All experimentation at site 3 ceased at passage 3
due to detection of cell culture contamination. The co-
efficient of variation (CV) data demonstrated that there are
significant differences in process outcome regarding the cell
numbers despite using the same process, machine and
Fig. 3 a Total number of cells per flask based on Cedex automated cell
counting (left axis) at different culture passage; variations in flask
numbers are the result of having to exclude one flask at passage 1 at
site 2 due to insufficient cell recovery post thawing. b Comparison of
flask-to-flask cell viability when expanded at multiple manufacturing
sites. c Percentage of co-efficient of variation (CV) for the total cell
number; black solid line represents site 1, blue dashed line represents
site 2, and red small dashed line represents site 3
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protocol across and within sites (Fig. 3C). This is a represen-
tative of an accumulation of the different sources of variation,
discussed at length in the following sections.
3.3 Cell phenotyping by flow cytometry
Flow cytometry was only performed on cells cultured at site 1;
the cells were unfortunately lost due to a courier error at site 2
and were terminated in the experiments performed at site 3.
Flow cytometry revealed a variation in the expression level of
all four pluripotency markers analysed when comparing
2102Ep cells at earlier and later passages.
SSEA-4 expression levels remained stable at approximately
97% when comparing flask-to-flask and passage numbers
(Fig. 4). The results were also comparable with the NIBSC in-
ternal standard 2102Ep cells and the hiPSC line NIBSC8. The
TRA-1-60 population positive percentage showed lower levels
of expression in the in-house 2102Ep cells when compared with
the n210EP-UKSCB internal standard sample but was higher
than the NIBSC8 control with average expression of approxi-
mately 54.7%; in comparison with 67% (n210EP-UKSCB
internal standard) and 48% (NIBSC8) expression respectively.
The result of Oct3/4 staining exhibited greater flask-to-flask
variation, and increased variation between earlier and later pas-
sages in comparison with the NIBSC standard samples (Fig. 4).
The average expression level was initially 59% at passage 1 and
subsequently 24% following the sixth passage. This potentially
correlates with the reduced cell viability, although this could also
be due to the cells starting to differentiate. A definitive reason for
this could not be determined since only pluripotency markers
were tested. Further experimentation would be required to rule
out the possibility of differentiation occurring. Oct 3/4 levels in
the NIBSC8 samples were much higher at 77% on average.
The transcription factor Nanog positive population percent-
age matched with the NIBSC8 samples (35% on average and
below 40% respectively) whilst the n210EP-UKSCB sample
expression level was reported much lower at approximately
10%. Overall, Nanog expression levels were reported as rela-
tively stable between different flasks and passage numbers.
The Nanog positive percentage expression was approximately
22% in flask 3 at passage 5, with the highest expression level
(47%) reported in flask 6 at passage 5.
N.B. All samples were subsequently destroyed, some due
to the lack of management oversight associated with academic
development settings.
4 Discussion
4.1 Cell line choice
Ideally, a clinically relevant pluripotent stem cell line, either
hESC or hiPSC, adapted to automated expansion, would have
been used for the comparability experiment. However, due to
Fig. 4 Flow cytometry analysis performed on cells cultured at site 1 based on the EC 2102Ep population positive percentage expression level of
pluripotency markers
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restrictions in Germany and France on the use of hESC, it was
necessary to use an alternative. Comparator cell line options
discussed included the Cellartis (now part of Takara Bio
Europe) SA001 hESC line. This cell line has been used to
derive keratinocytes stored in the cell banks at Passage 62,
and these cells had been adapted by I-Stem (one of the project
partners) to automate the expansion and differentiation to epi-
dermis protocols. Interactions with the wider community
working on pluripotent stem cells also occurred at the
Stockholm meeting of the Global Alliance for hiPSC
Therapies (GAiT) [18] in June 2015; however, the delegates
were not able to suggest an available iPSC line of clinical
relevance at that time.
The UK Stem Cell Bank (UKSCB), part of the UK
National Institute for Biological Standards and Control
(NIBSC, [20]), was represented at GAiT [18]. The
NIBSC have a mission for developing biological refer-
ence materials. Researchers at the UKSCB had been
working to develop the EC 2102Ep line as a reference
material (i.e. a ‘ruler line’) to be used for developing
and qualifying processes and equipment. Whilst close
to being thought of as an emulation of an embryonal
stem cell line, it is not considered to have the sensitivity
to culture conditions associated with these and therefore
cannot be viewed as a comprehensive standard. It has
been previously characterised by Josephson et al.
(2007) [21]. EC 2102Ep was consequently chosen as
the best available reference line.
4.2 Cell count and viability
Cell count and viability varied from flask to flask and from site
to site. Apart from the previously mentioned deviations and
differences in the manufacturing sites and the CompacT
SelecT machine specification, there are other possible expla-
nations for cell count variation. One possible explanation is
that errors in cell count occurred due to the high percentage of
cell aggregate formation. The selection of dissociation agents
and an optimisation of cell detachment duration is required to
minimise the formation of cell aggregates. Another reason for
an error in cell number could be due machine capability lim-
itations and the number and duration of pipette mixing steps.
Although the number of pipette mixing steps and mixing du-
ration were adjusted, and optimised, numerous cell aggregates
were still visible following the mixing step. Furthermore, the
CompacT SelecT default pipette size is 10 ml, which is not
suitable for breaking down the cell aggregates into single
cells; therefore, a change in manufacturing design of pipette
holder is needed for smaller liquid handling volumes, poten-
tially to include the use of 2-ml pipettes. In addition, Cedex
the automated cell count device could be a possible source of
error. Cedex utilises the Trypan blue reagent for count and
viability, by introducing a parallel cell count using more
advanced cell counting devices such as the NucleoCounter
NC-3000™. This would reduce the potential error, whilst gen-
eratingmore comparable and accurate cell counts and viability
recordings. The initial flask-to-flask variation in cell count that
occurred at all sites suggested differences in recovery from
cryopreservation and/or during the manual thawing process.
4.3 Cell phenotyping by flow cytometry
A comparison of the phenotype data from site 1 and NIBSC
(control data) suggested that the variant of the EC 2102Ep
may not be sufficiently stable for the use as a standard cell
line. This was evidenced by variation and discrepancies in the
expression of pluripotency markers (Fig. 4). These challenges
have previously been recognised and reported [21]. This could
be further exacerbated by the automated culture protocol due
to the removal of the centrifugation step. The expression of the
pluripotency markers SSEA-4, TRA-1-60, Oct3/4 and Nanog
did not remain sufficiently stable from passage-to-passage and
flask-to-flask variations were observed. However, such
changes may also be a consequence of the low cell viability/
poor growth rate rather than the stability of the cell line.
4.4 Relationship between total cell count and viability
The cell count and viability analyses revealed considerable
variability across three sites and between passages.
Although the experiment had to be terminated at passage
3 at site 3, the reduction in total cell count coincided with
the reduction in cell viability that occurred between pas-
sages 2 and 3. Despite the spike in total cell count that was
recorded at passage 4 at site 1, from passage 5 onwards
both total cell count and viability decreased. It was ob-
served that the decline in cell viability that occurred be-
tween passages 4 and 5 at site 2 also coincided with a
reduction in cell count. However, three of the six flasks
showed an increase in cell viability at passage 6, despite
the total cell count declining to less than 0.5 × 106 cells/ml.
4.5 Deviations
This experiment has allowed for the identification of devia-
tions, the types of potential deviations and an assessment of
their impact. This demonstrates that the experiment was more
representative of preparatory engineering runs for operational
qualification (OQ), process qualification (PQ) and validation
purposes. The third phase of our experiment was anticipated
to allow the comparison of the output of stable production
runs. However, we were not able to progress the experi-
ment fully through the envisaged third phase because of
deviations. The deviations observed in the experiment are
discussed in detail below.
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4.5.1 Deviations in manufacturing and deviations
in regulated manufacturing
It is appropriate to consider process deviation in a convention-
al manufacturing context. People, machines and systems exe-
cute process protocols step by step; even if the individual steps
are complex within themselves, these steps take the process
and product from state to state. Some deviations may be con-
sequences of installation differences. A process deviation oc-
curs when the state achieved at the next step is not the desired
state. Process deviations can be of different types. Some pro-
cess deviations are fatal and it is clear that the product must be
scrapped. In other circumstances, it may be possible to repair
the product by a subsequent rework process. However, it is
also possible in some cases to recover the process or product
within the individual machine or system. Recovery returns the
system to the desired state either at the same or next step/s
using conditional contingency actions that depend on the ac-
tual system state.
Informal discussions within the UK as the experiment
progressed amplified the regulatory perspective particularly
with respect to actions that can be taken after a deviation in
multiple site settings. These were predicated by the assump-
tions that each site had equivalent equipment qualified in the
same way, that starting and raw materials were qualified, and
that the product produced must not breach pre-set specifica-
tions within clinical trial or marketing authorisation. This dis-
cussion emphasised that the level of discretion permitted to
the qualified person (QP) in the handling of deviations is cur-
rently controversial and open to interpretation, with the need
for significant training on individual sites, and that the han-
dling of unexpected deviations was complex and difficult. The
need for decisions to be made quickly and sometimes remote-
ly poses further challenges. The need for increased vigilance
to monitor for deviations once known was emphasised in this
demonstrator experiment. This highlighted the requirements
for thorough failure mode and effect analysis (FMEA) to be
performed in the process design.
Should this approach be taken such actions must nec-
essarily be within the defined path in the clinical trial or
marketing authorisation.
4.5.2 Anticipated and unexpected outcomes
As previously described (Table 4), several differences be-
tween sites were initially identified and several key actions
were initiated to minimise the variance between sites present-
ed here as an Ishikawa or fish-bone diagram (Fig. 5). These
actions were typically those that would have beenmanaged by
the installation, commissioning and qualification, training,
maintenance and preventative maintenance (PM) processes.
This included machine repair and the requirement for subse-
quent overall equipment effectiveness (OEE) growth before
the equivalent of process qualification (PQ). This required
considerable interaction with the supplier, with some delays
resulting from the lack of engineering resource. Overall, the
implemented actions were able to set the machines at the dif-
ferent sites into the desired state, which was confirmed by a
‘wet run’. The experiment demonstrated that there was little
clarity of specification and the range of settings across the sites
gave reduced achievable range. Consequently, this resulted in
a tighter process specification across the sites. This drifting
increase of constraints is known by some as the ‘specification
trap’. Further compromises between sites were also required
due to differences in quality systems, this included approaches
to asepsis, different work patterns and engineering changes
due to differences in site layout. For instance, site layouts
meant that there were differences in the length of feed tubing.
An agreement on a common agreed core process protocol was
also necessary.
A protocol was initially written at site 1 and distrib-
uted to all sites for the CompacT SelecT automated
process; any deviations were identified, and local spe-
cific changes were included and approved, i.e. the in-
clusion of an inspection step; ensuring that the process
was equivalent at the three sites. However, insufficient
attention was paid to gathering and compiling the ex-
pertise of operators at all sites into the final agreed
common protocol. This emphasised the requirement for
an inclusive responsibility for the writing of all SOPs as
part of the process transfer process.
As the experiment progressed many more deviations be-
came apparent, Fig. 6 summarises these. During the installa-
tion and operational qualification (IQ and OQ) and PQ equiv-
alent preparatory periods including engineering runs, many
software-driven deviations arose including the consequences
of software and machine interactions. Whilst a number of
these were due to gaps in the experience of the engineering
team, some were a consequence of use the of the flexible
software intensive sub-systems with redundancy—error-
prone features—and of the use of custom software. These
are strong signals for machine designers and programmers
seeking to exploit programmable components (for instance
the handling robot at the core of the machine) that permit fast
machine design and create more generic process development
platforms to focus on robust code design and on coding steps
that may raise errors.
Given that the materials used in advanced therapeutic me-
dicinal product (ATMP) manufacturing can be very rare—a
single patient sample that forms the process starting material
for instance—as discussed above it is necessary to consider
whether such contingency actions should be permitted in au-
tomated production systems. Keeping in mind that such inter-
ventions maybe very difficult in closed automated systems.
An example of such a contingency action encountered in this
experiment is a manual intervention following a machine
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failure to extract a flask from the machine and to manually
pipette out the contents to permit recovery of the product at the
last process step. Clearly from a comparability perspective for
this particular experiment, each site would have to use the
same contingency actions, themachine and process is required
to be returned to its desired state in the same way at all sites.
The consequences of such in-process interventions, with re-
spect to product risk must be understood and managed.
As the experiment progressed further, some significant un-
planned deviations arose with the consequences of risk to the
product. Themost visible of these was obvious contamination,
echoing industry level discussions on the prevention of
Fig. 5 Ishikawa or fish-bone diagram illustrating the anticipated and known manufacturing process deviations identified at the start of the experiment
grouped into broad areas and by individual issues
Fig. 6 Ishikawa or fish-bone diagram illustrating the unexpected manufacturing process deviations that only became apparent following experimental
runs grouped into broad areas and by individual issues
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microbial and virial contamination [21], with a clear require-
ment to scrap the product. This highlighted that the process
should be closed to reduce risk, however, in the protocol
employed in this work, conventional T-flasks were used.
Other deviations were associated with incubator atmosphere
failure. These would be preventable in a manufacturing setting
via preventative maintenance and more attention to OEE.
The most challenging and difficult to manage deviation
was the observation of a low-level contamination at different
levels in cultures at one site, the consequences of this on
growth rate are shown in Fig. 3. This echoes recent observa-
tions made in the production of preclinical trials batches [28].
In order to mitigate this deviation, it is suggested that post-
process visual microscopic morphological comparison is per-
formed, in this instance ‘post-processing’ refers to the com-
pletion of each process step, i.e. medium exchange and cell
passage. Specifically, following the completion of each pro-
cess step, the operator should collect a sample of excess cell
suspension from each cell flask. This sample medium requires
visual examination via light microscopy to determine the pres-
ence of any discrepancies. This can include media turbidity,
pH deviations (as indicated by the phenol red indicator) and
the presence of any floating debris.
These unexpected deviations highlighted the need for
(real-time) monitoring techniques to permit early identifi-
cation of incipient contamination and re-emphasised the
need for agreed visual controls to permit a light microsco-
py and imaging approach to this, the most familiar ap-
proach to biological scientists. This capability is included
in second-generation machines. The initial protocol as-
sumed that operators would visually examine the cultures,
an imaging step was subsequently added to assist commu-
nication between sites. Subsequently, this step was critical
when assessing potentially contaminated cultures. This in
turn identified a requirement to have consistent visual stan-
dards as part of the SOP that all parties would interpret in
the same way. These visual standards are required to rep-
resent all potential states of the culture. Such standards are
still required for automated imaging. Furthermore, it is rec-
ommended that in-house randomised in-depth analysis
using quantitative analytical techniques including qPCR
and metabolite analysis screening are performed to act as
an additional quality control measure to definitively ensure
that culture sterility. An additional level of process scrutiny
would be the inclusion of routine external sterility testing
to identify issues before and during the process.
Noting that the original master and working cell banks
were mycoplasma-tested, investigation showed that con-
tamination did not appear to be across the whole of the
experimental working bank and highlighted the need to
be able to non-destructively monitor individual vials.
Further investigations were compromised by cold storage
and courier issues but indicated that not all the cryovials
used in the experiment were contaminated. The discus-
sion that arose as a consequence of the incipient contam-
ination and the lack of clarity on whose role it was to
authorise the termination of the culture process con-
firmed the need for a carefully structured quality system
across the sites with clear roles for local, remote and
overseeing decision-makers (i.e. the equivalent of the
QP in the experiment) and escalation procedures. The
difficulty in establishing the original source/s of contam-
ination highlights the need for strict, comprehensive
quality control of the master banks; followed by contin-
uous qualification of the working banks. Furthermore,
there is a requirement to monitor the condition of vials
as they travel through the supply chain.
The nature of ‘unexpected deviations’ and how they
are dealt with highlights the requirement for a quality
system that will change with time, which emphasises
the importance of change management protocols across
sites. Consideration of candidate corrective and preven-
tative actions for the low-level contamination explored
the following: (i) the delivery of the product to the
pat ient with ant ibiot ics ( recent ly discussed at
Phacilitate [24]) is under the guidance of the treating
physician; however, this may pose the risk of litigation
as has recently occurred in the USA [11] following a
regulatory recall [22]. This approach also does not ad-
dress viral contamination. (ii) The culture of the product
with antibiotics; this, however, may mask other issues
within the culture and again does not address issues of
viral contamination. (iii) The qualification of the starting
bank to agreed enhanced standards. (vi) The improve-
ment of the current process by taking the steps of pro-
cess closure, ensuring that all processes within the
whole of the overall materials handling and storage
chain do not allow contamination, and the development
of agreed visual controls and other, contamination or
risk-specific, check or routine monitoring techniques
(i.e. sterility testing to identify issues).
Further discussion on monitoring raised the consideration
that, for every process step completed by the machine, there
should be an additional check step within the machine; this
could be achieved via the machine itself or an additional in-
ternal process within the machine system and that the results
of the check should form part of the batch record. Ensuring the
quality of open manual interventions must also be considered,
for instance using a two-person ‘buddy’ system to view and
check all actions. An instance of this is the use of a checker to
check, view and confirm compliance to the SOP in addition to
updating manufacturing batch records in real time [8, 12],
especially given that the QP is reliant upon the batch record
to release the product. The financial consequences of these
issues are significant as is the requirement, in the multiple site
settings, for a local quality assurance organisation in which in
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the QP can be confident. Figure 7 summarises these ‘do dif-
ferents’ and other learning points from the project that form
key areas for further work.
4.6 Contamination
This experiment has emphasised the issues associated
with contamination, especially low-level, uncharacteristic
contamination, and how this should be managed in a mul-
tiple sites setting within a European regulatory context.
The term ‘uncharacteristic’ refers to the fact that during
this experiment, whilst there were contaminations in cell
cultures, there was no medium clouding or turbidity ob-
served in any of the cultures. These are normally seen in
many cultures with bacterial contamination [23].
To address this, the first step is the establishment of a
‘central’ QP role and the identification and recruitment of a
QP sensitive to the issues of manufacturing at multiple
sites. The QP is required to determine operator roles and
requirements, this is inclusive of specific training require-
ments based on a defined set of competencies. The role of
the QP must be agreed across all sites since they will as-
sume ultimate responsibility for the manufacturing pro-
cess. Similarly, the roles and expectations of all operators
across all sites must to be defined, agreed and formalised
contractually. This contract is an agreement by all opera-
tors to ensure that no deviations in timings, process param-
eters or incidents due to personal circumstances may occur.
In situations where operator roles may deviate, for example
due to illness, relocation, staff turnover or change of employ-
ment, the QP should to be notified with as much notice as
possible. For clinical trials or marked production, given their
responsibility for product release, the QP should have the final
authority on reassignment of operator roles and responsibili-
ties and whether operators are appropriately qualified. This
should not be the decision of the individual sites, but the QP
should consider the input of individual site operators and local
quality personnel. Similarly, any decisions with regard to how
to manage contamination must ultimately be decided by the
QP, using all recorded data. The QP should be able to request
additional testing if required.
This experiment has highlighted the importance of im-
aging data. In the experiment described here, individual
operators had, or were, assuming the responsibility of mak-
ing decisions with regard to continuation of manufacturing
when contamination occurred, for example, when only one
flask was showing signs of contamination; this responsi-
bility should be removed from the individual. Ideally such
decisions should be made by an on-call QP, not the opera-
tor. However, it is acknowledged that this may not be fea-
sible in all instances, thus there is a requirement for a qual-
ity hierarchy; it is recommended that there is an additional
QA resource that can act as an auxiliary to the QP at every
site with carefully designed responsibility who reports in a
timely way to a QP at a centralised location.
The clear ultimate responsibility of the QP for any deci-
sions regarding the manufacturing process, training and
Fig. 7 Ishikawa or fish-bone diagram illustrating post project learning or ‘do differents’ to be considered for future manufacturing scenarios, grouped
into broad areas and by individual issues
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competency requirements, and Corrective Action Preventive
Action (CAPA) should help avoid stigma associated with con-
tamination or process failures especially when addressed with-
in a quality improvement framework. There should be an
agreed acceptance across all operators and sites that contam-
ination is an inevitable risk of cell manufacturing and should
be reported immediately to the QP without questioning of the
operator’s cell culture practice given that there are many
sources for contamination. A single database is required for
the recording of contamination or process failures across all
sites. A standardised format of reporting and paperwork
would allow the QP to identify and analyse general trends
and common areas of error or contamination.
Prior to the onset of any extended processing, a detailed
screening and re-qualification of banks is recommended; this
should occur in a single centralised unit to avoid deviations in
protocols and analysis. This process could also be blinded to
avoid any potential bias in analysis and teams involved should
include manufacturing and quality representatives of each site
involved. All operator training needs should be reviewed and
signed off centrally by the QP or their representative.
Experimentation and extended processing are only to com-
mence upon completion and sign-off of operator training re-
cords. The training documentation is a record that each oper-
ator has demonstrated and completed all the required compe-
tencies required to work with the defined cell line and proto-
cols associated. Training is required for all involved in the cell
manufacturing process, irrespective of their role; this is to be
complemented by peer-to-peer, buddy, observation and note-
taking. All aspects from manual handling to automation need
to be covered during the training procedure; progression to
automated culture can only occur once manual culture com-
petencies has been signed off by the QP.
It is vital that all prior training is specific to the cell line
being manufactured, the process protocol and production
system, and the product; a one-size fits all approach is not
appropriate. In order to ensure and determine that cell spe-
cific parameters such as cell growth rate and viability are
recognised by all operators and across all sites, pre-run ex-
periments should be designed. This will enable a consensus
regarding a cell line–specific standard range of acceptable
growth rates, viability and phenotype expression. This strat-
egy circumvents any biological discrepancies and deviation
during actual process runs since any deviations and poten-
tial errors that fall outside of the agreed operation window
process limits will be identified and recorded during train-
ing and process development. Additionally, a mathematical
modelling approach can be applied to predict the growth
rate and dynamics of specific cell lines and determine the
critical process parameters (CPPs) that affect the metabolite
concentration, viability and growth. Such parameters in-
clude cell density, composition of bulk media, presence
and concentration of growth factors, the timing and
frequency of feeding. This approach can also be used in
predicting the effect of variation in temperature and incuba-
tion time. The results of this approach can be recorded in a
centralised database to permit the establishment of agreed
limits for biological process deviation across sites.
During the product/process development and training
processes, all operators should record and report poten-
tial areas for error, process deviation and risk. These are
to be reported using a standardised format on a
centra l ised database to be viewed by the QP.
Ultimately a single, detailed SOP that includes the risk
mitigations identified should be prepared. The use of
decision-process flowcharts for the SOP should be con-
sidered for steps of the process where conditional ac-
tions are acceptable. This should address the entire
manufacturing process, and the conditions for terminat-
ing the culture process made explicit. Accompanying
the process SOP, there is a requirement for a
harmonised and uniform SOP for machine and equip-
ment maintenance, synchronised to usage and workload.
This will serve as a means to reduce points of failure
regarding equipment and machine malfunction, whilst
also ensuring that all processing tools are serviced, cal-
ibrated and equivalent across sites.
This experiment was carried out by a collaboration of
manufacturing aware development organisations with strong
translational missions. Despite these common goals, each or-
ganisation had different perspectives and cultures. In retrospect,
each institute should have run an in-depth risk assessment of
potential process and equipment deviations and any potential
sources of and areas of risk for contamination. It would have
been particularly helpful if the in-depth risk assessment also
involved the wider laboratory teams. This should have been
followed by sharing and discussion of proposals for mitigation
by the three sites together and these, when agreed by all orga-
nisations and approved by the QP equivalent, included within
the SOP prior to the onset of any work commencing. Once
agreed, no deviations to the SOP are permitted unless they
are progressed through appropriate change control.
5 Conclusions
Establishing how to effectively manufacture cell therapies is
an industry level problem. Decentralised manufacturing is of
increasing importance and its challenges are recognised by
healthcare regulators with deviations receiving specific atten-
tion from them. This paper is the first to report the deviations
and other risks encountered when implementing comparabil-
ity of expansion of human pluripotent stem cells in an auto-
mated three international site–decentralised manufacturing
setting. In addition to identifying practically encountered pro-
cess deviations and how they may be addressed the work has
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identified incipient process failures including low-level con-
tamination that are intrinsically difficult to manage and exac-
erbated by a decentralised process. In summary, it has
highlighted the following issues:
& The practical difficulties associated with the choice of a
representative and stable cell line to be used as a
manufacturing standard.
& All sites involved are required to contribute to a single
agreed SOP to permit learning from all sites to be consid-
ered and ensure that all sites are aligned behind the proto-
col. Expertise and training differences between sites must
be addressed to ensure all sites are competent.
& Compromises may be required between sites to minimise
variations due to different work patterns and differences in
legal and regulatory frameworks.
& Resolving differences between sites pre- and post-
preventative maintenance required significant supplier in-
teraction; therefore, supplier capacity issues need to be
considered as part of a realistic project planning.
Differences between sites may reduce the practical allow-
able process window.
Differences and deviations are particularly apparent in a
multiple site setting, deviations identified in this work and
the actions required to address them include:
& Identification of equipment failures and the need for
recommissioning.
& Timely interventions for process recovery.
& The consequences of use of flexible software intensive
sub-systems.
& Differences in cell culture process output.
& Agreed visual controls via light microscopy machine im-
aging written into the protocol.
& Consistent representative visual standards as part of the
SOP that all parties would interpret in the same way.
These visual standards are required to represent all poten-
tial states of the culture.
& Correction of deviations in the same way at all sites—and
critically agreement of the cause across sites.
& Common quality system including QP structure capable
of evolution with time.
& Manual processes require the use of check steps and oper-
ator buddies, these have significant financial implications.
& In process sterility monitoring should be present, but may
impact product yields due to the significant requirements
for sampling.
This experiment has confirmed where key components and
additional costs of GMP are added to the basic costs of the cell
culture manufacturing process, and particularly showmultiple
sites production requires additional QA resource. Automation
is an obvious way forward in the manufacturing of ATMPs
because of its scalability, but it is necessary to be clear about
the problems to be solved for it to be unquestionably applied
as an alternative to manual processing. This paper has espe-
cially emphasised the requirement for monitoring steps to be
included within the machine system.
As a final comment, it should be noted that the level of
effort required to execute this project was significantly
underestimated by the project partners. The level of budget
required to completely validate a distributed manufacturing
multiple sites manufacturing strategy would only be justified
in commercial settings where the financial return is signifi-
cant. Further work is still required however to better under-
stand how to design a compliant multiple site process valida-
tion approach that is cost effective.
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